Valbiotis joins forces with Aika for a strategic partnership in Asia

Valbiotis, a French pharmaceutical company, has announced an alliance with the Chinese group Aika to create a joint venture. This partnership aims to market ValbiotisPRO healthcare products in several Asian markets starting in 2026. The joint venture, 49% owned by Valbiotis and 51% by Aika, will initially focus on a cross-border e-commerce (CBEC) model in China and other key territories. A conventional distribution channel will then be considered after obtaining the necessary regulatory approvals. This initiative underscores a strategy of international growth in expanding markets such as China and Singapore.